Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

CMCSA vs CVS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CMCSA Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 6–4 Matrix Metrics)

CMCSA Overall Winner 6-Pillar Tally: CMCSA 5 – 1 CVS Matrix Metrics: CMCSA 6 – 4 CVS

As of Nov 20, 2026, Comcast Corp (CMCSA) is the stronger overall head-to-head candidate over Cvs Health Corporation (CVS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CMCSA carries a Unified Composite Score of 32.8/100 (SELL) at $24.90 (7.1x Forward P/E, 14.7% operating margin), whereas CVS carries 62.6/100 (BUY) at $80.84 (9.3x Forward P/E, 3.1% operating margin).

  • Composite vs. Pillar Nuance: While CVS currently prints a higher short-term Unified Composite Score (62.6/100 BUY vs. CMCSA 32.8/100 SELL), CMCSA captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (14.7% vs. 3.1% operating margin) and revenue trajectory (-6.1% vs. +5.4% YoY).
  • Technical & Structure Timing Caution: CMCSA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 59.9); meanwhile CVS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CMCSA vs CVS
CMCSA NASDAQ Head-to-Head Winner
Comcast Corp
Cable & Other Pay Television Services
$24.90
+0.16% 1D
Market Cap $88.3B
TTM Revenue $123.0B
Forward P/E 7.1x
Beta / 30D Vol -0.01β · 32% Vol
Unified Composite Score
32.8 / 100 SELL
Tech 20.0 Fund 44.0 Flow 59.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 60
RSI-14: 59.9 · SMA20: $24.14 · SMA50: $22.92
CVS NYSE
Cvs Health Corporation
Retail-Drug Stores And Proprietary Stores
$80.84
+1.0% 1D
Market Cap $102.4B
TTM Revenue $418.2B
Forward P/E 9.3x
Beta / 30D Vol -0.03β · 54% Vol
Unified Composite Score
62.6 / 100 BUY
Tech 65.0 Fund 62.0 Flow 58.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.5%), weak momentum, RSI 37
RSI-14: 36.8 · SMA20: $86.94 · SMA50: $88.43

6-Pillar Scorecard Institutional Category Breakdown (CMCSA 5 – 1 CVS)

Columns: Metric · CMCSA · CVS
1. Valuation Multiples CMCSA
Forward P/E 7.1x 9.3x
Trailing P/E 7.9x 9.3x
PEG Ratio 1.37x 0.20x
EV / Revenue 1.4x 0.4x
2. Growth & Scale CVS
Revenue Growth (YoY) -6.1% +5.4%
Earnings Growth (YoY) +7.8% +188.8%
TTM Revenue (USD) $123.0B $418.2B
Market Cap $88.3B $102.4B
3. Profitability & Quality CMCSA
Gross Margin 69.8% 13.7%
Operating Margin 14.7% 3.1%
Net Profit Margin 9.2% 2.6%
Return on Equity (ROE) 11.4% 14.4%
4. Balance Sheet & Cash Flow CMCSA
Cash Generation (TTM) $17.1B $15.6B
Cash Flow Margin 13.9% 3.7%
Net Cash / Leverage $79.8B Net Debt (0.94x D/E) $63.6B Net Debt (0.94x D/E)
Dividend Yield 5.23% 3.27%
5. Options & Positioning CMCSA
Options Structure Phase CONSOLIDATION CONSOLIDATION
Current IV / %ile 36.3% (30th %ile) 86.2% (69th %ile)
Put/Call OI Skew 0.41x (Call-Skewed) 0.62x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat CMCSA
OpEx & R&D Intensity 55.1% of Rev ($67.8B) 10.6% of Rev ($44.3B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Telecom Services Operator Healthcare Plans Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CMCSA (6) vs CVS (4)
Institutional Metric CMCSA CVS Criterion Row Edge
Market Capitalization
Scale
$88.3B $102.4B Larger Scale CVS
Trailing P/E Ratio
Valuation
7.9x 9.3x Lower Multiple CMCSA
Forward P/E Ratio
Valuation
7.1x 9.3x Lower Multiple CMCSA
Revenue Growth (YoY)
Growth
-6.1% +5.4% Higher Growth CVS
Operating Margin (TTM)
Profitability
14.7% 3.1% Higher Margin CMCSA
Net Profit Margin
Profitability
9.2% 2.6% Higher Margin CMCSA
Return on Equity (ROE)
Capital Efficiency
11.4% 14.4% Higher ROE CVS
52-Week Range Position
Momentum
36% ($20–$33) 28% ($70–$111) Stronger Trend CMCSA
Beta / 30D Volatility
Risk Regime
-0.01β · 32% Vol -0.03β · 54% Vol Lower Realized Risk CMCSA
Unified Institutional Score
Composite Signal
32.8 / 100 (SELL) 62.6 / 100 (BUY) Higher Composite CVS
Trailing 12M Revenue (USD)
Operating Scale
$123.0B $418.2B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
69.8% 13.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.37x PEG · 1.4x EV/Rev 0.20x PEG · 0.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$17.1B ($79.8B Net Debt (0.94x D/E)) $15.6B ($63.6B Net Debt (0.94x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CMCSA +23.46 pp
CMCSA: +9.02% · CVS: -14.44%
3M Horizon CMCSA +6.25 pp
CMCSA: -7.85% · CVS: -14.1%
6M Horizon CMCSA +12.11 pp
CMCSA: -1.21% · CVS: -13.32%
1Y Horizon CVS +12.93 pp
CMCSA: -7.33% · CVS: +5.6%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CMCSA Revenue CVS Revenue CMCSA Op. Margin CVS Op. Margin Margin Leader
FY2018 $94.5B $193.9B 20.1% 2.1% CMCSA
FY2019 $108.9B $256.8B 19.4% 4.7% CMCSA
FY2020 $103.6B $268.7B 16.9% 5.2% CMCSA
FY2021 $116.4B $292.1B 17.9% 4.6% CMCSA
FY2022 $121.4B $322.5B 11.6% 2.5% CMCSA
FY2023 $121.6B $357.8B 19.2% 3.8% CMCSA
FY2024 $123.7B $372.8B 18.8% 2.3% CMCSA
FY2025 $123.7B $402.1B 16.7% 1.2% CMCSA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CMCSA CONSOLIDATION
61d in phase · OBV NEUTRAL
Current IV 36.3%
IV Percentile 30th %ile
Put/Call OI Skew 0.41x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact CMCSA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CVS CONSOLIDATION
104d in phase · OBV DISTRIBUTION
Current IV 86.2%
IV Percentile 69th %ile
Put/Call OI Skew 0.62x (Call-Skewed)
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact CVS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $25.60 · IV 34.7%

CMCSA vs. CVS: Simulated 5-Day Option Payoffs & Capital Efficiency

Compare 100 shares of CMCSA ($2,560) vs. CVS ($8,859) against risk-defined 5-day vertical and put-wall option structures.

CMCSA Spot $25.60 · IV 34.7%
CMCSA Options Simulator →
5-DAY BULLISH SWING Liq A

Dec 18 $25 / $27.5 Bull Call Spread

Buy 1x $25C · Sell 1x $27.5C · 31d

Net Entry $104 Debit
T+5d @ +5% Move +$47 (+46%)
Max Risk / Buffer $104 Capped
5d Edge & Liquidity 0.9x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $24 / $22.5 Bull Put Spread

Sell 2x $24P · Buy 2x $22.5P · 31d

Net Entry $56 Credit
Max Credit / Yield +$56 (+23.0% RoM)
Max Risk / Buffer -7.3% Cushion ($244 Mgn)
5d Edge & Liquidity 75% PoP · Liq A
Simulate 5-Day Payoff →
CVS Spot $88.59 · IV 29.7%
CVS Options Simulator →
5-DAY BULLISH SWING Liq A

Dec 18 $87.5 / $95 Bull Call Spread

Buy 1x $87.5C · Sell 1x $95C · 31d

Net Entry $290 Debit
T+5d @ +5% Move +$170 (+58%)
Max Risk / Buffer $290 Capped
5d Edge & Liquidity 0.9x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $85 / $80 Bull Put Spread

Sell 1x $85P · Buy 1x $80P · 31d

Net Entry $101 Credit
Max Credit / Yield +$101 (+25.3% RoM)
Max Risk / Buffer -5.2% Cushion ($399 Mgn)
5d Edge & Liquidity 71% PoP · Liq A
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CMCSA Moat Profile Cyclical / Execution-Driven Positioning
Telecom Services Operator
Competes within the Telecom Services value chain with $88.3B market capitalization and 14.7% operating margin.
OpEx & R&D Reinvestment 55.1% of Rev ($67.8B)
90D Engineering Disclosures 0 Published
CVS Moat Profile Cyclical / Execution-Driven Positioning
Healthcare Plans Operator
Competes within the Healthcare Plans value chain with $102.4B market capitalization and 3.1% operating margin.
OpEx & R&D Reinvestment 10.6% of Rev ($44.3B)
90D Engineering Disclosures 0 Published

Investor FAQ CMCSA vs CVS Key Questions & Quantitative Answers

As of Nov 20, 2026, Comcast Corp (CMCSA) is the stronger overall head-to-head candidate over Cvs Health Corporation (CVS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CMCSA carries a Unified Composite Score of 32.8/100 (SELL) at $24.90 (7.1x Forward P/E, 14.7% operating margin), whereas CVS carries 62.6/100 (BUY) at $80.84 (9.3x Forward P/E, 3.1% operating margin). Composite vs. Pillar Nuance: While CVS currently prints a higher short-term Unified Composite Score (62.6/100 BUY vs. CMCSA 32.8/100 SELL), CMCSA captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (14.7% vs. 3.1% operating margin) and revenue trajectory (-6.1% vs. +5.4% YoY). Technical & Structure Timing Caution: CMCSA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 59.9); meanwhile CVS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CVS leads the Growth & Scale pillar: CMCSA posts -6.1% YoY revenue growth and +7.8% YoY earnings growth on $123.0B TTM revenue (69.8% gross margin, 14.7% operating margin), compared with CVS at +5.4% YoY revenue growth and +188.8% YoY earnings growth on $418.2B TTM revenue (13.7% gross margin, 3.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CMCSA cumulative revenue shifted +30.9% while CVS shifted +107.3%. In operating R&D and SG&A reinvestment, CMCSA deploys 55.1% of Rev ($67.8B) (0 90-day corporate R&D disclosures) versus 10.6% of Rev ($44.3B) (0 disclosures) for CVS.

CMCSA screens cheaper on headline valuation multiples. CMCSA trades at 7.1x Forward P/E, 7.9x Trailing P/E, 1.37x PEG, and 1.4x EV/Revenue (13.9% FCF margin), whereas CVS trades at 9.3x Forward P/E, 9.3x Trailing P/E, 0.20x PEG, and 0.4x EV/Revenue (3.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CMCSA (11.4% ROE) versus CVS (14.4% ROE) capital efficiency.

In options market volatility and institutional positioning, CMCSA carries 36.3% implied volatility (30th %ile, Balanced (25th–60th %ile)), a 0.41x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (-0.01β · 32% Vol realized risk). By comparison, CVS carries 86.2% implied volatility (69th %ile, Elevated (60th–80th %ile)), a 0.62x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (-0.03β · 54% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.